However, the compensatory effect of the AR signaling pathway through bypass signaling leads to poor efficacy and a high recurrence rate of prostate cancer treatment relying on the AR pathway, which also indicates that AR signaling pathway-associated lncRNAs that can be used as efficient prostate cancer therapeutic targets have yet to be explored. Here, AR is linked to prostate carcinoma.